Compare Bristol-Myers Squibb Co (BMY) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while iShares 10 20 Year Treasury Bond ETF trades at $96.56. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while iShares 10 20 Year Treasury Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | TLH | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Fixed Income |
52-Week High | $65.89 | $105.36 |
52-Week Low | $42.60 | $96.39 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
TLH trades at $96.57, up 0.19% today, with a bearish technical signal from moving averages and neutral oscillators. Recent dividends include $0.38 (July 2026), $0.36 (June 2026), and $0.41 (May 2026). Key financial ratios like P/E and ROE are unavailable, limiting fundamental clarity. Support and resistance cluster near $96-$97, indicating tight price consolidation amid weak momentum.
The outlook is cautious due to missing financial metrics and bearish technicals. Risks include reliance on dividend stability and macroeconomic pressures from rising yields. Opportunities may arise if fundamentals improve, but current data suggests limited upside without clearer earnings visibility or positive analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
